Researchers Robinson, Murphy and Friedman identified that CBD, or cannabidiol, is not clinically used as a Treatment option for Common Dermatological Issues, such as, psoriasis, atopic dermatitis and wound healing. Their study concentrated on a twenty question online survey to examine dermatologists’ knowledge, attitude and perception of therapeutic CBD.

Of the 531 respondents, 86% believed that CBD should be used for medical treatment, while 94% believed that it was important to research dermatologic uses of CBD.  55% of respondents indicated that they had at least one patient initiate the conversation of CBD as a treatment option during the previous year.

Even with this positive feedback from the medical community, 48% stated that they were concerned about a negative stigma by proposing CBD to patients. Many respondents (86%) were willing to prescribe an FDA-approved topical treatment but only 71% were willing to prescribe an FDA-approved oral form. Only 36% of respondents indicated that they knew that CBD was not psychoactive and 29% did not know tetrahydrocannabinol (THC) is psychoactive.

Based on these survey results, it appears that patients and dermatologists are interested and ready for CBD to treat common Dermatological Issues, however, the knowledge base is lacking. Dermatologists require further education and additional testing requires completion to concretely identify the benefits and risks of dermatologic CBD.

To read the full article discussed above, please click here.